Science Corporation, led by Max Hodak, former president of Neuralink, has successfully raised $230 million in a Series C funding round. This funding brings the company’s post-money valuation to $1.5 billion, indicating strong investor confidence in its work in the brain-computer interface space.
Science Corp’s key innovation, PRIMA, is a tiny chip designed to restore functional vision in individuals with advanced macular degeneration. Through successful trials involving 47 patients in Europe and the U.S., 80% of participants experienced significant improvements in visual acuity, enabling them to read letters, numbers, and words.
The company’s approach involves implanting PRIMA in the eye, where it interacts with camera-equipped glasses to enhance the user’s vision. By leveraging technology acquired from Pixium Vision and further refining it, Science Corp has positioned itself at the forefront of brain-computer interface technology development.
With a CE mark application already submitted to the European Union, Science Corp anticipates approval by mid-2026, paving the way for PRIMA’s market launch in Europe. This milestone could establish the company as the first to offer a brain-computer interface product to consumers, marking a significant advancement in the field of neural interfaces.
Source: TechCrunch